饮食与生活方式医学委员会（EAT）-柳叶刀委员会饮食与代谢功能障碍相关脂肪性肝病及其他肝脏慢性疾病风险：英国生物银行的一项大型前瞻性队列研究

EAT-Lancet diet and risk of metabolic dysfunction-associated steatotic liver disease and other liver chronic diseases: a large prospective cohort study in the UK Biobank.

作者信息

Wu Shi-Yi, Bo Ya-Cong, Li Ze-Yang, Hu Xing-Yue, Ning Yang-Yang, Huang Jia, Zhang Jun-Xi, Zhu Yong-Jian, Yu Zeng-Li, Liu Hong-Yan

机构信息

Department of Medical Genetics, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.

College of Public Health, Zhengzhou University, Zhengzhou, China.

出版信息

Front Nutr. 2025 Jul 31;12:1589424. doi: 10.3389/fnut.2025.1589424. eCollection 2025.

DOI:10.3389/fnut.2025.1589424

PMID:40823023

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12350129/

Abstract

BACKGROUND AND AIM

As a newly recommended healthy dietary blueprint, the EAT-Lancet diet emphasizes both environmental sustainability and human health. However, its impact on chronic liver diseases remains unclear. This study examined the influence of the EAT-Lancet diet on the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and other chronic liver diseases.

METHODS

Our study included 160,394 UK Biobank participants who completed 24-h dietary assessments between April 2009 and June 2012, from which EAT-Lancet diet scores were calculated. The Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for the primary outcome (MASLD) and secondary endpoints, including cirrhosis, liver cancer, and other liver diseases.

RESULTS

A total of 1,727 cases of MASLD, 602 cases of liver cirrhosis, 103 cases of liver cancer, and 2,053 cases of other liver diseases were identified over a median follow-up period of 13.3 years. Using the lowest tertile as the reference, the highest EAT-Lancet diet index group demonstrated a 33% reduction in MASLD incidence (HR:0.67, multivariate 95%CI: 0.55, 0.80). In several secondary outcome measures, similar associations were also observed. Furthermore, the risk of MASLD was lowest among individuals with both higher EAT-Lancet dietary scores and lower genetic risk (HR = 0.52; 95%CI: 0.36-0.74), although no significant interaction was detected between the two groups.

CONCLUSION

Adherence to the EAT-Lancet diet is associated with a reduced risk of chronic liver disease, independent of genetic factors.

摘要

背景与目的

作为一项新推荐的健康饮食蓝图，《柳叶刀》饮食强调环境可持续性和人类健康。然而，其对慢性肝病的影响仍不明确。本研究探讨了《柳叶刀》饮食对代谢功能障碍相关脂肪性肝病（MASLD）及其他慢性肝病风险的影响。

方法

我们的研究纳入了160394名英国生物银行参与者，他们在2009年4月至2012年6月期间完成了24小时饮食评估，并据此计算出《柳叶刀》饮食得分。采用Cox比例风险模型估计主要结局（MASLD）和次要终点（包括肝硬化、肝癌及其他肝病）的风险比（HR）及95%置信区间（CI）。

结果

在中位随访期13.3年期间，共识别出1727例MASLD、602例肝硬化、103例肝癌及2053例其他肝病病例。以最低三分位数为参照，《柳叶刀》饮食指数最高组的MASLD发病率降低了33%（HR：0.67，多变量95%CI：0.55，0.80）。在几项次要结局指标中也观察到了类似的关联。此外，《柳叶刀》饮食得分较高且遗传风险较低的个体发生MASLD的风险最低（HR = 0.52；95%CI：0.36 - 0.74），尽管两组之间未检测到显著的相互作用。